QUEBEC CITY, Feb. 22 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS)
(TSX: AEZ) (the "Company"), a late-stage drug development company
specialized in oncology and endocrinology, announced today that it has
filed a prospectus supplement dated February 22, 2011 to its U.S. shelf
prospectus, dated March 12, 2010, forming part of its U.S. registration
statement on Form F-3 with the United States Securities and Exchange
Commission ("SEC") as well as a prospectus supplement to its Canadian
final base shelf prospectus dated March 12, 2010.
Aeterna Zentaris has entered into an "At-the-Market" ("ATM") Sales
Agreement, dated February 22, 2011, with McNicoll, Lewis & Vlak LLC
("MLV"), under which the Company may, at its discretion, from time to
time during the 24-month term of the agreement, sell up to a maximum of
12,500,000 of its common shares through ATM issuances on the NASDAQ
Stock Market not to exceed US$19.8 million, being the aggregate amount
remaining available for distribution under the Company's current F-3
registration statement. MLV will act as sales agent for any sales made
under the ATM. The common shares will be sold at market prices
prevailing at the time of a sale (if any) of the common shares, and, as
a result, prices may vary. The Company is not required to sell any of
the reserved shares at any time during the term of the ATM.
The U.S. shelf prospectus and the supplement thereto have been filed
with the SEC on the SEC's website (www.sec.gov) and the Canadian final base shelf prospectus and the supplement
thereto have been filed on the SEDAR website maintained by the Canadian
Securities Administrators at www.sedar.com. Alternatively, MLV will provide copies of the U.S. documents upon
request by contacting McNicoll, Lewis & Vlak LLC, Attention: Randy
Billhardt, 420 Lexington Avenue, New York, NY 10170, or by calling
212-580-5881, while copies of the Canadian documents may be obtained by
contacting the Company's Investor Relations department directly by
calling (418) 652-8525, ext. 265.
This press release does not and shall not constitute an offer to sell or
the solicitation of an offer to buy any of the common shares, nor shall
there be any sale of the common shares in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of such state
About Aeterna Zentaris Inc.
Aeterna Zentaris is a late-stage oncology drug development company
currently investigating potential treatments for various cancers
including colorectal, ovarian, endometrial cancer and multiple myeloma.
The Company's innovative approach of "personalized medicine" means
tailoring treatments to a patient's specific condition and to unmet
medical needs. Aeterna Zentaris' deep pipeline is drawn from its
proprietary discovery unit providing the Company with constant and
long-term access to state-of-the-art therapeutic options. For more
information please visit www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.
For further information:
Investor Relations Coordinator
(418) 652-8525 ext. 265
Director of Communications
(418) 652-8525 ext. 406